Comorbidity scores are increasingly used to reduce potential confounding in oncologic researches. This is of paramount importance in endometrial cancer (EC) since it is characterized by quite indolent behavior. Here, we aim to evaluate the impact of various comorbidities and concurrent medications used on survival outcomes, adopting the age-adjusted Charlson comorbidity index (A-CCI).
Age-Adjusted Charlson Comorbidity Index Predicts Survival in Endometrial Cancer Patients / DI DONATO, Violante; D'Oria, Ottavia; Giannini, Andrea; Bogani, Giorgio; Fischetti, Margherita; Santangelo, Giusi; Tomao, Federica; Palaia, Innocenza; Perniola, Giorgia; Muzii, Ludovico; BENEDETTI PANICI, Pierluigi. - In: GYNECOLOGIC AND OBSTETRIC INVESTIGATION. - ISSN 0378-7346. - (2022). [10.1159/000525405]
Age-Adjusted Charlson Comorbidity Index Predicts Survival in Endometrial Cancer Patients
Violante Di Donato;Ottavia D’Oria;Andrea Giannini;Giorgio Bogani;Margherita Fischetti;Giusi Santangelo;Federica Tomao;Innocenza Palaia;Giorgia Perniola;Ludovico Muzii;Pierluigi Benedetti Panici
2022
Abstract
Comorbidity scores are increasingly used to reduce potential confounding in oncologic researches. This is of paramount importance in endometrial cancer (EC) since it is characterized by quite indolent behavior. Here, we aim to evaluate the impact of various comorbidities and concurrent medications used on survival outcomes, adopting the age-adjusted Charlson comorbidity index (A-CCI).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
